GLP-1 SM + Cagri-RC

This research blend combines two structurally distinct metabolic-pathway research peptides — a GLP-1 receptor-agonist reference analog (Semaglutide) and an amylin / calcitonin receptor-agonist reference analog (Cagrilintide) — supplied together as a single lyophilized reference material for combined metabolic-pathway research. The peer-reviewed literature catalogs this combination class within paradigms that examine incretin signaling alongside amylin-receptor signaling in the same experimental session, letting investigators dissect the contribution of each receptor family to downstream metabolic dynamics. Each component’s molecular identity is characterized individually on the supplier’s Certificate of Analysis; the GLP-1 component corresponds to PubChem CID 56843331 and the amylin-class component to PubChem CID 171397054. The blend is supplied for laboratory characterization, in-vitro receptor-binding work, and in-cell signaling studies only. For research use only; not for human consumption, medical use, or veterinary application.

The blend’s combined molecular profile is the sum of two distinct peptide architectures documented across the published literature. The GLP-1 component is a multi-residue peptide analog with backbone-stabilizing substitutions and a C18 fatty-diacid acylation moiety that drives extended plasma residence through albumin binding, engaging the GLP-1 receptor and its cAMP / PKA signaling cascade. The amylin-class component is a multi-residue cyclic peptide with an intramolecular disulfide bridge preserving the bioactive conformation characteristic of native amylin, also fatty-acid-acylated for extended plasma residence, engaging calcitonin-receptor / RAMP heteromer cAMP signaling. The two components activate non-overlapping class B GPCR families documented in the literature. All activity descriptors here are framed as documented in published research rather than as effects of the supplied product.

Experimental domains documented in the published literature for combined incretin-and-amylin research paradigms include parsing GLP-1-receptor signaling from amylin-receptor (RAMP-CTR heteromer) signaling within the same experimental session, β-cell signaling investigations under combined agonism, hepatocyte-and-pancreatic-cell signaling studies, integrated metabolic-pathway research in animal-model contexts, and structure-activity work probing how distinct receptor families integrate downstream metabolic dynamics. Investigators use blended research materials of this kind to study the additive-versus-synergistic question across two GPCR families. Use in laboratory research extends to mechanism-elucidation paradigms where the blend serves as a defined dual-mechanism metabolic-pathway reference. The blend is supplied for these and equivalent in-vitro and animal-model experimental contexts only, with no associated guidance for human, clinical, or veterinary use.

Each component of the blend is characterized individually before combination. Reverse-phase HPLC is performed on the lyophilized blend to verify the relative composition ratio of the two components, with each component identified by its characteristic retention time and confirmed by mass spectrometry molecular-ion match against the empirical formulas reported on the COAs. The acylation site and fatty-diacid stoichiometry of each component are confirmed by tandem mass spectrometry when included in the release specification. Disulfide-bond integrity of the cyclic amylin-class component is confirmed by reduction-and-alkylation methods when included in the release specification. Purity is reported as combined HPLC-area composition on the blend’s Certificate of Analysis. The COA records the lot identifier, the relative amount of each component as supplied, the manufacturing date, and analytical method versions used. Researchers requiring component-level analytical detail should reference the individual component reference standards.

For laboratory storage, the lyophilized blend should be held at −20°C in its sealed, light-protected container until ready for analytical use. Allow vials to equilibrate to ambient temperature before opening to avoid moisture condensation on the lyophile. Reconstitution for in-vitro experimental use is typically performed in bacteriostatic water or a researcher-selected buffer compatible with the downstream assay; once reconstituted, store the working solution at 2–8°C and characterize stability in the relevant buffer prior to extended storage. Acylated peptide analogs may exhibit aggregation behavior in some buffer systems — assay-specific stability characterization for both components is recommended. The intramolecular disulfide bridge of the cyclic component is sensitive to reducing conditions — avoid reductant-containing buffers unless specifically required by the assay. Avoid repeated freeze-thaw cycles. These handling parameters do not constitute preparation guidance for human or veterinary use.